A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

A Phase I Open-label, Multicenter Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with CLDN6-positive locally advanced or metastatic solid tumors.

Study Overview

• Status: Completed
• Conditions: Solid Tumor
• Intervention / Treatment: Drug: SAIL66

• Study Type: Interventional
• Enrollment (Actual): 22
• Phase: Phase 1

Contacts and Locations

Study Locations

• Japan
  • Chiba
    • Kashiwa, Chiba, Japan, 277-8577
      • National Cancer Center Hospital East
  • Chuo Ku
    • Tokyo, Chuo Ku, Japan, 104-0045
      • National Cancer Center Hospital
  • Koto Ku
    • Tokyo, Koto Ku, Japan, 135-8550
      • Cancer Institute Hospital Of JFCR
  • Sunto-gun
    • Shizuoka, Sunto-gun, Japan, 411-8777
      • Shizuoka Cancer Center
• United States
  • Arizona
    • Gilbert, Arizona, United States, 85234
      • Banner MD Anderson Cancer Center
  • Georgia
    • Augusta, Georgia, United States, 30912
      • Georgia Cancer Center at Augusta University
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • MUSC Hollings Cancer Center
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Tennessee Oncology, PLLC
  • Texas
    • Houston, Texas, United States, 77030
      • The University of Texas MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥ 18 years at time of signing Informed Consent Form
• Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1
• Patient must have tumor specimen available for central pathology review and confirmed as CLDN6-positive
• (For male patients) Agreement to stay abstinent or use contraceptive measures with female partners, and agreement to refrain from donating sprerm during the treatment

Exclusion Criteria:

• Intending to become pregnant or breastfeed during the study and within 3 months after the last dose of SAIL66 or tocilizumab, whichever is longer
• Primary central nervous system (CNS) malignancy, symptomatic (seizures etc.) CNS metastases or CNS metastases required any anti-cancer treatment
• History or presence of CNS disease such as stroke (e.g., subarachnoid hemorrhage or cerebral infarction), epilepsy, CNS vasculitis, neurodegenerative disease, aphasia, dementia or paresis
• Uncontrolled tumor-related pain
• Uncontrolled pleural effusion, pericardial effusion, or ascites

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Expansion part; Patients will receive SAIL66 as a IV infusion at the recommended dose.	Drug: SAIL66; SAIL66 as a IV infusion
Experimental: Q3W Dose Escalation part; Patients will receive SAIL66 as tri-weekly IV infusions at escalated doses.	Drug: SAIL66; SAIL66 as a IV infusion
Experimental: QW Dose Escalation part; Patients will receive SAIL66 as a weekly IV infusion at escalated doses.	Drug: SAIL66; SAIL66 as a IV infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events of SAIL66[safety and tolerability]	Incidence, nature, and severity of adverse events graded according to NCI Common Terminology CTCAE v5.0, with severity of CRS determined according to the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Criteria	From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Change from baseline in vital signs[safety and tolerability]	Change from baseline in vital signs	From screening until study completion or treatment discontinuation (approximately 18 weeks)
Change from baseline in clinical laboratory test results and examination findings[safety and tolerability]	Change from baseline in clinical laboratory test results and examination findings specified in this study including, but not limited, electrocardiograms (ECGs)	From screening until study completion or treatment discontinuation (approximately 18 weeks)
Preliminary anti-tumor activity of SAIL66 when administered at selected dose(s) in each cohort [Expansion part]	Objective response rate (ORR), defined as the proportion of patients with a confirmed complete response (CR) or partial response (PR) on two consecutive occasions >= 4 weeks apart, assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 by the investigators.	From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Dose-limiting toxicities (DLTs) of SAIL66[safety and tolerability]	Incidence and nature of the DLTs [Q3W Dose Escalation part and QW Dose Escalation part]	From Cycle 1 Day 1 until Cycle 1 Day 21 (Cycle 1 is 21 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of response (DoR)[preliminary efficacy]	Duration of response (DoR), defined as the time from the first occurrence of CR or PR to progression disease (PD) or death from any cause (whichever occurs first), per the investigator according to RECIST v.1.1	From the first occurrence of CR or PR to progression disease (PD) or death from any cause (whichever occurs first)(whichever occurs first) (approximately 18 weeks)
Disease control rate (DCR)[preliminary efficacy]	Disease control rate (DCR), defined as the proportion of patients who have CR, PR, or stable disease (SD) as best overall response per RECIST v.1.1 as determined by the investigator. SD must be confirmed at the first tumor assessment as scheduled in Appendix 1 after the start of treatment (the minimum duration for SD).	From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Progression-free survival (PFS)[preliminary efficacy]	Progression-free survival (PFS), defined as the time from administration of first study treatment to the first occurrence of disease progression or death from any cause, as determined by the investigator according to RECIST v.1.1	From administration of first study treatment to the first occurrence of disease progression or death from any cause (approximately 18 weeks)
Immunogenicity of SAIL66[preliminary efficacy]	Incidence of ADAs to SAIL66 and potential correlation with PK parameters and safety	From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation (approximately 18 weeks)
Overall survival (OS)[preliminary efficacy]	Overall survival (OS), defined as the time from administration of first study treatment to death from any cause [Expansion part]	From administration of first study treatment to death from any cause (approximately 18 weeks)
Objective response rate(ORR)[preliminary efficacy]	ORR assessed per RECIST v.1.1 by the investigators. [Q3W Dose Escalation part and QW Dose Escalation part]	From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Maximum serum concentration (Cmax) of SAIL66 [PK profile]	Maximum serum concentration (Cmax) of SAIL66	From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Trough serum concentration (Ctrough) of SAIL66 [PK profile]	Trough serum concentration (Ctrough) of SAIL66	From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Area under the concentration time-curve (AUC) of SAIL66 [PK profile]	Area under the concentration time-curve (AUC) of SAIL66	From the first occurrence of CR or PR to progression disease (PD) or death from any cause (whichever occurs first) (approximately 18 weeks)

Collaborators and Investigators

• Sponsor: Chugai Pharmaceutical
• Investigators: Study Director: Sponsor Chugai Pharmaceutical Co. Ltd, clinical-trials@chugai-pharm.co.jp

Study record dates

Study Major Dates

• Study Start (Actual): April 17, 2023
• Primary Completion (Actual): January 26, 2026
• Study Completion (Actual): January 26, 2026

Study Registration Dates

• First Submitted: January 27, 2023
• First Submitted That Met QC Criteria: February 9, 2023
• First Posted (Actual): February 21, 2023

Study Record Updates

• Last Update Posted (Actual): March 10, 2026
• Last Update Submitted That Met QC Criteria: March 9, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Antineoplastic Agents, Immunological; Antineoplastic Agents; Obinutuzumab
• Other Study ID Numbers: SAL101JG

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform. For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No